NeuroPace, Inc. NPCE R2K
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 30.0% over 5 years.
- Profit CAGR of 18.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NPCE NeuroPace, Inc. R2K | 16.54 | - | $563.91M | - | -15.96% | -111.38% | 29.99% | 18.14% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.97M | 7.64M | 12.77M | 11.22M | 12.63M | 10.34M | 11.37M | 10.20M | 11.16M | 14.47M | 16.51M | 16.43M | 18.12M | 19.26M | 21.06M | 22.52M | 23.52M | 27.35M | 26.59M | 22.07M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.18M | 5.39M | 6.19M | 6.01M | 4.02M |
| Gross Profit | 7.06M | 5.42M | 9.57M | 8.49M | 9.36M | 7.51M | 8.26M | 7.47M | 7.96M | 10.37M | 11.97M | 12.23M | 13.34M | 14.13M | 15.42M | 17.34M | 18.13M | 21.17M | 20.58M | 18.05M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.49M | 24.96M | 23.77M | 22.34M | 23.62M |
| Operating Income | -5.46M | -3.45M | -1.17M | -3.87M | -4.61M | -6.24M | -9.76M | -10.97M | -10.20M | -8.32M | -7.85M | -5.95M | -7.54M | -6.23M | -4.24M | -5.15M | -6.82M | -2.60M | -1.77M | -5.57M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.97M | -6.12M | -1.36M | -607.00K | -4.66M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.15M | 2.06M | 1.65M | 1.60M | 1.52M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.59M | -8.65M | -3.50M | -2.73M | -6.69M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.74M | -8.79M | -4.13M | -8.81M | -8.49M | -8.08M | -11.46M | -12.69M | -11.79M | -10.38M | -9.12M | -7.26M | -8.93M | -7.51M | -5.45M | -6.59M | -8.65M | -3.50M | -2.73M | -6.69M |
| Diluted EPS | -33.32 | -43.44 | -19.26 | -32.73 | -0.48 | -0.34 | -0.47 | -0.52 | -0.48 | -0.41 | -0.36 | -0.28 | -0.32 | -0.26 | -0.19 | -0.21 | -0.26 | -0.11 | -0.08 | -0.20 |
| R&D Expense | 4.83M | 3.25M | 3.69M | 4.10M | 4.44M | 4.33M | 5.58M | 5.67M | 5.61M | 5.26M | 5.34M | 4.79M | 5.78M | 6.07M | 5.75M | 7.44M | 6.84M | 6.58M | - | 7.19M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 41.14M | - | 45.52M | 65.42M | 79.91M | 99.99M |
| Cost of Revenue | - | - | 13.03M | 17.30M | 20.82M | 22.77M |
| Gross Profit | 30.27M | - | 32.49M | 48.12M | 59.09M | 77.22M |
| Operating Expenses | - | - | 73.29M | 75.30M | 80.76M | 93.56M |
| Operating Income | -13.05M | - | -40.79M | -27.17M | -21.67M | -16.34M |
| EBITDA | - | - | -36.57M | -22.83M | -16.57M | -12.06M |
| Interest Expense | - | - | 7.53M | 8.52M | 8.80M | 7.46M |
| Pretax Income | - | - | -47.08M | -32.96M | -27.14M | -21.46M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -24.28M | - | -47.08M | -32.96M | -27.14M | -21.46M |
| Diluted EPS | -117.85 | -2.17 | -1.91 | -1.27 | -0.93 | - |
| R&D Expense | 15.70M | 18.21M | 21.95M | 20.78M | 23.65M | 27.89M |
Compounded Sales Growth
| 5 Years: | 29.99% |
| 1 Year: | -2.00% |
Compounded Profit Growth
| 5 Years: | 18.14% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +25.11% |
| 6 Months: | -0.96% |
| 3 Months: | +13.44% |
| 1 Month: | +0.00% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 55.95M | - | 114.11M | 107.65M | 94.65M | 105.56M |
| Current Assets | - | - | - | 97.71M | 92.72M | 81.34M | 94.07M |
| Cash & Equivalents | - | 26.39M | - | 6.61M | 18.06M | 13.43M | 21.69M |
| Inventory | - | - | - | 9.71M | 11.21M | 13.38M | 16.90M |
| Receivables | - | - | - | 7.48M | 12.31M | 12.85M | 14.68M |
| Total Liabilities | - | 62.36M | - | 79.33M | 87.00M | 86.63M | 86.53M |
| Current Liabilities | - | 9.60M | - | 10.98M | 16.23M | 15.16M | 17.81M |
| Long Term Debt | - | 50.82M | - | 52.91M | 56.95M | 59.52M | 58.88M |
| Total Debt | - | - | - | 69.77M | 72.39M | 73.34M | 70.84M |
| Total Equity | -129.35M | -147.83M | - | 34.78M | 20.65M | 8.01M | 19.03M |
| Shares Outstanding | - | - | - | 25.05M | 27.82M | 30.15M | 33.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.61M | - | -36.87M | -19.70M | -17.95M | -11.01M |
| Investing Cash Flow | -10.77M | - | 23.80M | 23.03M | 8.99M | -332.00K |
| Financing Cash Flow | 55.01M | - | 490.00K | 8.13M | 4.33M | 19.60M |
| Capital Expenditure | -62.00K | - | -603.00K | -173.00K | -306.00K | -332.00K |
| Free Cash Flow | -21.67M | - | -37.47M | -19.87M | -18.25M | -11.34M |
| Net Change in Cash | - | - | -12.58M | 11.45M | -4.63M | 8.26M |
| Share Buybacks | - | - | - | - | 0 | 49.55M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 73.6% | - | 71.4% | 73.6% | 73.9% | 77.2% |
| Operating Margin % | -31.7% | - | -89.6% | -41.5% | -27.1% | -16.3% |
| Net Margin % | -59.0% | - | -103.4% | -50.4% | -34.0% | -21.5% |
| ROE % | 16.4% | - | -135.4% | -159.6% | -338.7% | -112.8% |
| ROCE % | -28.2% | - | -39.6% | -29.7% | -27.3% | -18.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Polar Capital Holdings PLC | 9.67% | 3.30M | $54.55M |
| 2 | Soleus Capital Management, L.P. | 8.60% | 2.93M | $48.50M |
| 3 | Morgan Stanley | 7.53% | 2.57M | $42.46M |
| 4 | First Light Asset Management, LLC | 7.22% | 2.46M | $40.69M |
| 5 | Blackrock Inc. | 6.88% | 2.35M | $38.81M |
| 6 | Orbimed Advisors LLC. | 6.15% | 2.10M | $34.68M |
| 7 | Driehaus Capital Management, LLC | 4.26% | 1.45M | $24.01M |
| 8 | Vanguard Capital Management LLC | 3.30% | 1.12M | $18.59M |
| 9 | Deutsche Bank AG | 2.73% | 932.09K | $15.42M |
| 10 | Armistice Capital, LLC | 2.03% | 692.00K | $11.45M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NPCE